SCHEMBL4667453

SCHEMBL4667453

COc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc5c(ccn5CC5CCN(C)CC5)c4)ncn3)cc2)cc1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.34
BCR P11274 5/20 0.34
IKBKE Q14164 5/20 0.34
TBK1 Q9UHD2 5/20 0.34
EGFR P00533 2/20 0.34
CYP19A1 P11511 1/20 0.33
BACE1 P56817 1/20 0.33
KDM1A O60341 2/20 0.33
HTR6 P50406 2/20 0.32
MEN1 O00255 2/20 0.32
USP2 O75604 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665687 0.91 MEN1 (0.39) ABL1BCREGFRKDM1AHTR6
SCHEMBL4664241 0.91 AXL (0.36) ABL1BCREGFRKDM1AHTR6
SCHEMBL4663796 0.88 ABL1 (0.36) ABL1BCRBACE1KDM1AMEN1
SCHEMBL4665806 0.88 MEN1 (0.36) ABL1BCREGFRBACE1KDM1A
SCHEMBL4666172 0.88 BPTF (0.42) EGFRHTR6MEN1USP2ALDH1A1
SCHEMBL4665748 0.88 EGFR (0.42) ABL1BCRIKBKETBK1EGFR
SCHEMBL4663907 0.87 KDM1A (0.34) ABL1BCREGFRBACE1KDM1A
SCHEMBL4664277 0.87 EGFR (0.43) ABL1BCRIKBKETBK1EGFR
Formic Acid SCHEMBL4667448 0.86 LMNA (0.41) ABL1BCRIKBKETBK1EGFR
SCHEMBL4667420 0.86 EGFR (0.39) ABL1BCREGFRBACE1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885IKBKE 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.